EMBRACE Trial Supports Spinraza’s Benefits in Broad Range of SMA Patients

EMBRACE Trial Supports Spinraza’s Benefits in Broad Range of SMA Patients

285086

EMBRACE Trial Supports Spinraza’s Benefits in Broad Range of SMA Patients

Treatment with Spinraza (nusinersen) was found to reduce the use of ventilation support and to improve motor function in symptomatic infants and children with infantile‐ or later‐onset spinal muscular atrophy (SMA), according to 2.5-year data from the Phase 2 EMBRACE trial. These infants and children had been ineligible to participate in other Spinraza trials. Yet, the findings are consistent with those reported for the ENDEAR trial (NCT02193074), involving patients with infantile-onset SMA, and the CHERISH trial…

You must be logged in to read/download the full post.